NAPLEX Quiz: Disease State Management

What this quiz covers

This quiz focuses on Disease State Management, giving you a quick way to practice the rules, question types, and explanations that matter most for NAPLEX.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Serum amylase and lipase every 3 months due to tramadol use
2. INR with warfarin dose adjustment and increased monitoring frequency due to interaction with amiodarone (correct answer)
3. Daily peak and trough warfarin concentrations to guide dosing
4. Routine platelet aggregation testing to assess aspirin-like effects of warfarin

Explanation: This question tests monitoring for drug interactions in elderly patients with atrial fibrillation. The key patient-specific factor is the interaction between warfarin and amiodarone, which potentiates anticoagulation via CYP inhibition, alongside elevated INR of 3.4 and bruising. Increased INR monitoring with dose adjustment is crucial per guidelines from ACCP, as amiodarone can increase INR by 25-50%, necessitating frequent checks to prevent bleeding. Serum amylase for tramadol is unnecessary without pancreatitis symptoms, while daily warfarin peaks/troughs are not standard. Platelet aggregation for aspirin effects misaligns with warfarin's mechanism. For similar interaction cases, anticipate pharmacokinetic changes and adjust monitoring frequency. Emphasize patient-centered care by educating on bleeding signs and adherence to appointments for safety.

Question 2

1. Counsel to use insulin glargine consistently every day at the same time, teach titration based on fasting SMBG, and review hypoglycemia recognition and treatment (correct answer)
2. Counsel to take insulin glargine only when fasting SMBG exceeds 200 mg/dL to prevent hypoglycemia
3. Counsel to stop metformin to reduce hypoglycemia risk and continue intermittent insulin use
4. Counsel to double insulin glargine dose on days when SMBG is high and skip the next day if low

Explanation: This question tests adherence counseling for basal insulin in type 2 diabetes with fear of hypoglycemia. The key patient-specific factor is inconsistent insulin use leading to high A1c of 10.8%, driven by misconceptions about hypoglycemia. Counseling on consistent daily use with titration is optimal per ADA guidelines, as basal insulin requires regularity for efficacy, with education reducing fears through recognition and treatment strategies. Intermittent or variable dosing promotes poor control and risks, while stopping metformin removes benefits. Doubling doses sporadically increases hypoglycemia. For similar adherence cases, address barriers like fear with education and self-monitoring. Emphasize patient-centered care by personalizing titration and hypoglycemia plans for safety and confidence.

Question 3

1. Add lisinopril 10 mg PO daily and monitor SCr and potassium in 1–2 weeks due to albuminuria and uncontrolled BP (correct answer)
2. Add clonidine 0.2 mg PO BID as first add-on because it lowers BP quickly
3. Add doxazosin 4 mg PO nightly because it improves kidney outcomes in diabetes
4. Increase amlodipine to 20 mg PO daily to reach BP goal

Explanation: This question tests the management of hypertension in patients with type 2 diabetes mellitus (T2DM) and concomitant albuminuria, emphasizing renoprotective strategies. The key patient-specific factors include uncontrolled blood pressure (150/92 mmHg), elevated urine albumin-to-creatinine ratio (UACR 120 mg/g indicating microalbuminuria), and preserved renal function (eGFR 85 mL/min/1.73 m²) with normal potassium (4.4 mEq/L). Adding lisinopril, an ACE inhibitor, is the optimal choice as guidelines from the American Diabetes Association (ADA) and American College of Cardiology (ACC) recommend ACE inhibitors or ARBs as first-line add-on therapy for hypertension in T2DM with albuminuria due to their proven renoprotective effects beyond blood pressure lowering. Increasing amlodipine to 20 mg daily is inappropriate as it exceeds the maximum recommended dose of 10 mg daily, potentially increasing adverse effects without additional benefit, while adding clonidine is not preferred as it is not a first-line agent and lacks renoprotective properties in this context. Similarly, doxazosin, an alpha-blocker, is not recommended for improving kidney outcomes in diabetes and is typically reserved for resistant hypertension or specific indications like benign prostatic hyperplasia. In similar cases, prioritize ACE inhibitors or ARBs in diabetic patients with albuminuria to slow progression of nephropathy, always monitoring serum creatinine and potassium to ensure safety. This approach underscores patient-centered care by balancing blood pressure control with organ protection, tailoring therapy to comorbidities like diabetes and renal involvement.

Question 4

1. Fill simvastatin 40 mg PO nightly as written; no interaction is expected with amlodipine
2. Recommend changing to atorvastatin 40 mg PO daily (or rosuvastatin 20 mg PO daily) due to interaction limiting simvastatin dose with amlodipine (correct answer)
3. Recommend changing to lovastatin 40 mg PO nightly to avoid CYP3A4 interactions
4. Hold amlodipine for 2 weeks after starting simvastatin 40 mg PO nightly

Explanation: This question tests the management of drug interactions between statins and calcium channel blockers. The key patient-specific factor is the concomitant use of amlodipine, which increases simvastatin exposure via CYP3A4 inhibition, limiting simvastatin to 20 mg daily. Recommending a switch to atorvastatin or rosuvastatin is optimal per FDA guidelines to avoid myopathy risk, as these statins are less affected by amlodipine and provide high-intensity therapy for LDL 168 mg/dL. Filling simvastatin 40 mg ignores the interaction and exceeds safe dosing, while switching to lovastatin worsens the interaction. Holding amlodipine risks uncontrolled hypertension. In similar interaction cases, prioritize alternative agents with favorable pharmacokinetics to minimize adverse effects. Promote safety by educating on muscle pain symptoms and the importance of reporting them promptly for patient-centered care.

Question 5

1. Start losartan 50 mg PO daily with counseling on angioedema precautions and monitor SCr and potassium in 1–2 weeks (correct answer)
2. Start aliskiren 300 mg PO daily because ACE inhibitors are contraindicated
3. Start lisinopril 10 mg PO daily at a low dose since angioedema is dose-related
4. Start spironolactone 50 mg PO daily as first-line renoprotective therapy in albuminuric CKD

Explanation: This question tests the selection of renoprotective antihypertensive therapy in patients with angioedema history. The key patient-specific factor is prior angioedema with lisinopril, contraindicating ACE inhibitors, alongside albuminuric CKD requiring renin-angiotensin blockade. Starting losartan is optimal as ARBs are recommended by KDIGO for CKD with albuminuria, with evidence from RENAAL trial showing renal protection, and monitoring ensures safety post-angioedema. Starting aliskiren is not first-line and contraindicated with diabetes, while retrying lisinopril risks recurrent angioedema. Starting spironolactone alone lacks primary renoprotection without RAS inhibition. For similar cases with drug intolerances, select alternatives within the same class if evidence supports safety. Emphasize patient-centered care by counseling on angioedema signs and regular lab monitoring to enhance adherence and prevent complications.

Question 6

1. Continue current regimen; falls are most likely due to osteoarthritis pain rather than medications
2. Discontinue diphenhydramine and diazepam, recommend nonpharmacologic sleep strategies, and reassess need for other sedating agents (correct answer)
3. Increase diphenhydramine to 75 mg PO nightly to improve sleep and reduce nighttime wandering
4. Switch diazepam to alprazolam 0.5 mg PO nightly PRN because it has a shorter half-life

Explanation: This question tests deprescribing in older adults with polypharmacy and fall risk. The key patient-specific factor is recent fall, orthostatic hypotension, and use of multiple sedating agents like diphenhydramine and diazepam in an elderly patient. Discontinuing these is optimal per Beers Criteria, which flag anticholinergics and benzodiazepines for fall risk, recommending nonpharmacologic alternatives for insomnia. Continuing the regimen overlooks deprescribing opportunities, while increasing diphenhydramine worsens anticholinergic burden. Switching to alprazolam maintains benzodiazepine risks without significant half-life benefits in elderly. In similar polypharmacy cases, apply Beers Criteria to identify and taper high-risk medications. Focus on safety by involving caregivers in non-drug strategies and monitoring for withdrawal to support patient-centered geriatric care.

Question 7

1. Add spironolactone 25 mg PO daily and monitor potassium and SCr within 1 week and again at 4 weeks (correct answer)
2. Increase chlorthalidone to 50 mg PO daily without additional monitoring
3. Switch lisinopril to aliskiren 300 mg PO daily due to persistent hypertension
4. Stop amlodipine and start verapamil ER 240 mg PO daily as the sole change

Explanation: This question tests the optimization of antihypertensive therapy in patients with resistant hypertension and diabetes. The key patient-specific factor is persistent BP elevation to 156/92 mmHg despite triple therapy, with normal potassium and eGFR indicating tolerance for mineralocorticoid receptor antagonists. Adding spironolactone is optimal as ACC/AHA guidelines recommend it for resistant hypertension, with evidence from PATHWAY-2 trial showing superior BP reduction, and monitoring is essential for hyperkalemia. Increasing chlorthalidone without monitoring risks electrolyte imbalances, while switching to aliskiren is contraindicated in diabetes due to hyperkalemia and renal risks. Stopping amlodipine for verapamil offers no clear benefit and may worsen control. For similar resistant hypertension cases, use a systematic add-on approach with close monitoring to achieve BP targets. Emphasize patient-centered care by discussing side effects like gynecomastia with spironolactone to improve adherence and safety.

Question 8

1. Add dapagliflozin 10 mg PO daily to reduce heart failure hospitalization risk (correct answer)
2. Switch lisinopril to sacubitril/valsartan 49/51 mg PO twice daily despite prior angioedema to improve outcomes
3. Start verapamil ER 240 mg PO daily to improve ejection fraction and symptoms
4. Add dapagliflozin 25 mg PO daily for additional heart failure benefit

Explanation: This question evaluates heart failure with reduced ejection fraction (HFrEF) management in a patient with documented angioedema to sacubitril/valsartan. The patient has HFrEF with LVEF 30% on appropriate beta-blocker and ACE inhibitor therapy but lacks SGLT2 inhibitor therapy, which is now guideline-recommended for all HFrEF patients regardless of diabetes status. Adding dapagliflozin 10 mg daily (A) is the optimal choice as SGLT2 inhibitors reduce heart failure hospitalization by approximately 30% and are recommended for all HFrEF patients, with dapagliflozin specifically approved at 10 mg daily for heart failure regardless of diabetes status or eGFR (down to 25 mL/min/1.73 m²). Switching to sacubitril/valsartan (B) is absolutely contraindicated with documented angioedema history. Verapamil (C) is contraindicated in HFrEF due to negative inotropic effects. Dapagliflozin 25 mg (D) is incorrect as the heart failure dose is 10 mg regardless of diabetes status. When managing HFrEF, ensure all four pillars of therapy are optimized (beta-blocker, ACE/ARB/ARNI, MRA, SGLT2 inhibitor), with SGLT2 inhibitors providing mortality and hospitalization benefits independent of glycemic effects.

Question 9

1. Add empagliflozin 10 mg PO daily as first add-on because it lowers A1c and weight
2. Add semaglutide 0.25 mg SC weekly and titrate as tolerated to improve A1c and support weight loss (correct answer)
3. Add canagliflozin 300 mg PO daily to maximize glucosuria and reduce UTI risk
4. Add glyburide 10 mg PO daily because it reduces UTI frequency

Explanation: This question tests the selection of add-on therapy for type 2 diabetes in patients with recurrent urinary tract infections. The key patient-specific factor is history of 3 UTIs in the last year, making SGLT2 inhibitors less favorable due to infection risk. Adding semaglutide is optimal as ADA guidelines prefer GLP-1 RAs for weight loss and glycemic control without increasing UTI risk, supported by LEADER trial evidence. Adding empagliflozin or canagliflozin heightens UTI risk via glucosuria, while glyburide offers no weight benefits and risks hypoglycemia. In similar cases with infection history, avoid agents exacerbating comorbidities. Promote safety by monitoring A1c and educating on lifestyle to support patient-centered diabetes management.

Question 10

1. Continue current regimen because anticholinergic effects are mild at these doses in older adults
2. Recommend deprescribing anticholinergic medications (e.g., taper amitriptyline and switch to duloxetine or gabapentin; consider mirabegron for OAB) to reduce delirium and constipation risk (correct answer)
3. Increase oxybutynin ER to 15 mg PO daily to reduce nighttime awakenings
4. Add diphenhydramine 25 mg PO nightly to help sleep while continuing all other medications

Explanation: This question tests deprescribing anticholinergic medications in older adults with delirium risk. The key patient-specific factor is recent confusion post-discharge, exacerbated by high anticholinergic burden from amitriptyline and oxybutynin in an elderly patient. Recommending deprescribing with alternatives is optimal per Beers Criteria, which associate anticholinergics with delirium and constipation, suggesting SNRIs or beta-3 agonists instead. Continuing the regimen ignores risks, while increasing oxybutynin worsens burden. Adding diphenhydramine compounds anticholinergic load. For similar geriatric cases, assess cumulative anticholinergic exposure using tools like the Anticholinergic Burden Scale. Emphasize patient-centered care by tapering slowly and monitoring symptoms to ensure safety and improve quality of life.

Question 11

1. Counsel that budesonide-formoterol should be used daily as maintenance to reduce inflammation and exacerbation risk, even when asymptomatic (correct answer)
2. Counsel to stop budesonide-formoterol and rely on albuterol because daily inhaled steroids cause dependence
3. Counsel to use budesonide-formoterol only before exercise and continue frequent albuterol use
4. Counsel to double the albuterol dose to 4 puffs q4h and stop controller therapy

Explanation: This question tests adherence counseling for controller medications in persistent asthma. The key patient-specific factor is underuse of prescribed budesonide-formoterol despite daily symptoms requiring frequent albuterol, indicating poor control. Counseling on daily use is optimal per GINA guidelines, as ICS/LABA maintenance reduces inflammation and exacerbations, with evidence showing better outcomes than PRN use alone. Stopping for albuterol reliance promotes steroid avoidance myths, while PRN or exercise-only use fails to address persistent inflammation. Doubling albuterol risks overuse side effects. In similar asthma cases, reinforce the importance of controllers for long-term control. Promote safety by teaching inhaler technique and action plans for patient-centered management.

Question 12

1. Start prednisone 40 mg PO daily for 5 days and add doxycycline 100 mg PO BID for 5 days, plus short-acting bronchodilator optimization (correct answer)
2. Start prednisone 5 mg PO daily for 30 days and avoid antibiotics to prevent resistance
3. Start amoxicillin-clavulanate 875/125 mg PO BID for 14 days without systemic corticosteroids
4. Start inhaled fluticasone monotherapy for immediate relief and stop tiotropium

Explanation: This question tests the management of acute COPD exacerbations with increased sputum and dyspnea. The key patient-specific factor is signs of infection (increased sputum, mild fever) without pneumonia, warranting systemic steroids and antibiotics. Starting prednisone and doxycycline with bronchodilator optimization aligns with GOLD guidelines, as short-course steroids reduce recovery time and antibiotics target bacterial causes in moderate exacerbations. Low-dose long-term prednisone risks side effects unnecessarily, while antibiotics alone omit anti-inflammatory benefits. Inhaled fluticasone monotherapy lacks acute relief. For similar exacerbation cases, assess severity and use guideline-directed therapy promptly. Emphasize patient-centered care by educating on early recognition and smoking cessation for safety and prevention.

Question 13

1. Advise taking glipizide only when skipping meals to prevent hypoglycemia
2. Recommend switching metformin to extended-release and using a once-daily routine (e.g., with dinner) to improve tolerability and adherence (correct answer)
3. Counsel to double the next dose of metformin after a missed dose to maintain glycemic control
4. Recommend stopping metformin immediately at the first sign of diarrhea and restarting at the same dose after symptoms resolve

Explanation: This question evaluates medication adherence strategies in type 2 diabetes management with poor glycemic control. The patient's A1c of 10.2% reflects significant non-adherence, missing approximately 40% of metformin doses and 20% of glipizide doses due to GI upset and complex scheduling with rotating work shifts. Recommending metformin extended-release with once-daily dosing (B) addresses both the GI tolerability issues and simplifies the regimen to improve adherence, as extended-release formulations reduce GI side effects by 50% and once-daily dosing improves adherence compared to twice-daily regimens. Advising glipizide only when skipping meals (A) is dangerous and could cause severe hypoglycemia. Doubling missed metformin doses (C) would worsen GI side effects and doesn't follow safe medication practices. Stopping metformin at first sign of diarrhea (D) would further compromise glycemic control and doesn't address the underlying adherence barriers. When addressing medication non-adherence, identify and systematically address specific barriers (side effects, complexity, scheduling) with evidence-based solutions like extended-release formulations and simplified dosing regimens rather than expecting behavior change alone.

Question 14

1. Start prednisone 40 mg PO daily for 5 days and start doxycycline 100 mg PO twice daily for 5 days (correct answer)
2. Start prednisone 10 mg PO daily for 14 days and continue current inhalers only
3. Start azithromycin 500 mg PO daily for 14 days without systemic corticosteroids
4. Discontinue budesonide/formoterol and start montelukast 10 mg PO nightly for symptom control

Explanation: This question tests the management of acute COPD exacerbation in a patient already on optimal maintenance therapy. The patient presents with increased dyspnea, sputum production, and hypoxemia (SpO2 90%), meeting criteria for a moderate COPD exacerbation requiring systemic corticosteroids and consideration of antibiotics. Starting prednisone 40 mg daily for 5 days with doxycycline (A) is the most appropriate treatment, as guidelines recommend 40 mg prednisone for 5 days for COPD exacerbations, and antibiotics are indicated when increased sputum purulence is present or in moderate-severe exacerbations. Low-dose prednisone for 14 days (B) provides inadequate anti-inflammatory effect and unnecessarily prolongs steroid exposure. Azithromycin alone without corticosteroids (C) fails to address the inflammatory component essential for exacerbation recovery. Discontinuing maintenance therapy (D) would worsen long-term control and montelukast has no role in COPD management. For COPD exacerbations, remember the "5-day/40 mg" prednisone regimen as standard of care, with antibiotics added for purulent sputum or moderate-severe presentations, while maintaining all chronic therapies.

Question 15

1. Serum potassium daily to detect hyperkalemia from heparin within 24 hours
2. Activated partial thromboplastin time (aPTT) or anti-Xa level per protocol and platelet count every 2–3 days to monitor for HIT (correct answer)
3. INR daily to titrate heparin infusion to goal 2–3
4. Serum amylase/lipase daily to monitor for heparin-induced pancreatitis

Explanation: This question evaluates appropriate monitoring parameters for unfractionated heparin therapy in a patient with renal dysfunction. The patient has CKD stage 3b (eGFR 32 mL/min/1.73 m²) and is receiving IV heparin for DVT treatment, requiring specific monitoring for both efficacy and safety. Monitoring aPTT or anti-Xa levels per protocol and platelet counts every 2-3 days (B) is essential for heparin management, as aPTT/anti-Xa ensures therapeutic anticoagulation while platelet monitoring detects heparin-induced thrombocytopenia (HIT), which occurs in 0.5-5% of patients typically between days 5-14. Daily potassium monitoring (A) is excessive as heparin-induced hyperkalemia develops gradually over days to weeks. INR monitoring (C) is incorrect as heparin doesn't affect INR; this parameter monitors warfarin therapy. Daily amylase/lipase (D) is unnecessary as heparin-induced pancreatitis is extremely rare. When initiating heparin therapy, establish baseline platelets and monitor every 2-3 days through day 14 or until discontinued, while using aPTT or anti-Xa to guide dosing, particularly important in renal dysfunction where drug accumulation may occur.

Question 16

1. Increase insulin glargine to 60 units SC nightly to target postprandial hyperglycemia
2. Add insulin lispro 4 units SC with the largest meal and titrate based on 2-hour postprandial SMBG (correct answer)
3. Discontinue metformin due to adequate fasting SMBG and continue basal insulin only
4. Switch insulin glargine to NPH 40 units SC nightly and keep other meds the same

Explanation: This question tests the intensification of insulin therapy in type 2 diabetes with postprandial hyperglycemia. The key patient-specific factor is well-controlled fasting glucose but elevated postprandial SMBG of 220–280 mg/dL, contributing to A1c of 8.6% despite basal insulin and metformin. Adding prandial insulin lispro is optimal as guidelines from ADA recommend adding bolus insulin to target postprandial excursions when basal insulin is maximized without hypoglycemia. Increasing basal insulin glargine primarily addresses fasting glucose, which is already adequate, and may increase hypoglycemia risk, while discontinuing metformin removes a beneficial sensitizer without justification. Switching to NPH offers no advantage over glargine and may worsen control due to peaking action. In similar insulin-requiring cases, use a stepwise approach starting with basal and adding prandial as needed for comprehensive glycemic control. Prioritize patient safety by teaching carbohydrate counting and hypoglycemia management to support self-care.

Question 17

1. Add pioglitazone 30 mg PO daily and continue current regimen
2. Add empagliflozin 10 mg PO daily and reassess A1c and renal function in 3 months (correct answer)
3. Increase glipizide XL to 20 mg PO daily as the primary next step
4. Add saxagliptin 5 mg PO daily without other changes

Explanation: This question tests the management of type 2 diabetes in patients with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). The key patient-specific factors are the presence of prior myocardial infarction, albuminuric CKD with eGFR 48 mL/min/1.73 m², and uncontrolled A1c of 9.2% despite metformin and glipizide. Adding empagliflozin is optimal as SGLT2 inhibitors are recommended by ADA and KDIGO guidelines for cardiorenal protection and glycemic control in such patients, with evidence from trials like EMPA-REG OUTCOME showing reduced CV events and CKD progression. Adding pioglitazone is less appropriate due to risks of fluid retention and heart failure in ASCVD patients, while increasing glipizide heightens hypoglycemia risk in CKD without cardiorenal benefits. Adding saxagliptin lacks the proven cardiorenal protection of SGLT2 inhibitors and requires dose adjustment for eGFR <50. In similar cases, prioritize agents with proven outcomes beyond glycemia, such as SGLT2 inhibitors or GLP-1 RAs, for high-risk patients. Emphasize patient-centered care by monitoring for side effects like genital infections and reassessing renal function regularly to ensure safety.

Question 18

1. Add spironolactone 25 mg PO daily as first-line add-on for uncontrolled hypertension in all patients
2. Start atorvastatin 40 mg PO nightly and recheck lipid panel in 4–12 weeks (correct answer)
3. Start simvastatin 10 mg PO nightly because high-intensity statins are not recommended in diabetes
4. Start atorvastatin 80 mg PO twice daily to more rapidly reduce LDL

Explanation: This question addresses cardiovascular risk reduction in a patient with multiple risk factors including diabetes, hypertension, and dyslipidemia. The patient has an LDL of 172 mg/dL with diabetes, placing him in a high-risk category requiring statin therapy per ACC/AHA guidelines, with blood pressure also above goal (146/88 mmHg) and low potassium (3.4 mEq/L). Starting atorvastatin 40 mg nightly (B) is the most appropriate intervention as patients with diabetes aged 40-75 require at least moderate-intensity statin therapy, and this patient's LDL >70 mg/dL warrants high-intensity statin consideration, with follow-up lipid panel in 4-12 weeks to assess response. Adding spironolactone (A) might help blood pressure but addressing the significantly elevated LDL takes priority given cardiovascular risk, and potassium should be repleted first. Low-intensity simvastatin 10 mg (C) is inadequate for diabetes patients who require at least moderate-intensity therapy. Atorvastatin 80 mg twice daily (D) is incorrect as statins are dosed once daily, and 80 mg daily is the maximum dose. In diabetes management, prioritize statin therapy for all patients 40-75 years regardless of baseline LDL, with intensity based on ASCVD risk and LDL levels.

Question 19

1. Add lisinopril 10 mg PO daily and counsel to minimize NSAID use due to BP and renal effects (correct answer)
2. Switch hydrochlorothiazide to furosemide 20 mg PO daily as a stronger antihypertensive
3. Add clonidine 0.2 mg PO twice daily as the next step for resistant hypertension
4. Increase amlodipine to 20 mg PO daily to achieve BP goal

Explanation: This question evaluates the management of uncontrolled hypertension in a patient using chronic NSAIDs. The patient's blood pressure remains elevated (154/92 mmHg) despite two antihypertensive agents, with daily ibuprofen use likely contributing to treatment resistance through sodium retention and blunting of antihypertensive effects. Adding lisinopril (A) is the most appropriate choice as ACE inhibitors are recommended for hypertension management, and counseling to minimize NSAID use addresses the root cause of poor BP control while acknowledging the patient's osteoarthritis needs. Switching to furosemide (B) is inappropriate as loop diuretics are not preferred for uncomplicated hypertension and don't address the NSAID interaction. Clonidine (C) would be premature before optimizing current therapy and addressing NSAID use, and carries sedation risks. Increasing amlodipine to 20 mg (D) exceeds the maximum recommended dose of 10 mg daily. When managing hypertension in patients with chronic pain, always assess NSAID use as a reversible cause of treatment resistance and consider alternative pain management strategies while optimizing antihypertensive therapy with evidence-based agents.

Question 20

1. Add semaglutide 0.25 mg SC weekly and titrate as tolerated while continuing metformin (correct answer)
2. Add glyburide 5 mg PO daily due to low cost and potent A1c lowering
3. Add sitagliptin 100 mg PO daily as first choice for weight loss
4. Stop metformin and start insulin glargine 10 units SC nightly as monotherapy

Explanation: This question tests the selection of add-on therapy for type 2 diabetes in patients with obesity and a desire for weight loss. The key patient-specific factor is the patient's strong preference for weight loss, alongside uncontrolled A1c of 9.0% on metformin, with no ASCVD or heart failure. Adding semaglutide is optimal as GLP-1 receptor agonists are recommended by ADA guidelines for weight management and glycemic control, with evidence from trials like SUSTAIN showing significant weight loss and A1c reduction. Adding glyburide is inappropriate due to weight gain, hypoglycemia risk, and sulfonamide allergy cross-reactivity concerns, while adding sitagliptin offers minimal weight loss and less potent A1c lowering. Stopping metformin to start insulin glargine monotherapy risks weight gain and overlooks metformin's benefits in overweight patients. For similar cases, incorporate patient preferences into therapy selection to enhance adherence and outcomes. Focus on safety by educating on injection techniques and monitoring for gastrointestinal side effects to promote patient-centered care.